がんCDK阻害剤の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE1955)
◆英語タイトル:Global Cancer CDK Inhibitors Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE1955
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月
◆ページ数:96
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥546,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥819,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,092,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、がんCDK阻害剤の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(前臨床、フェーズI、フェーズI / II、フェーズII、フェーズIII)、用途別市場規模(医療機関、科学研究センター)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・がんCDK阻害剤の市場動向
・企業の競争状況、市場シェア
・がんCDK阻害剤の種類別市場規模(前臨床、フェーズI、フェーズI / II、フェーズII、フェーズIII)
・がんCDK阻害剤の用途別市場規模(医療機関、科学研究センター)
・がんCDK阻害剤の北米市場規模2016-2027(アメリカ、カナダ)
・がんCDK阻害剤の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・がんCDK阻害剤のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・がんCDK阻害剤の中南米市場規模2016-2027(メキシコ、ブラジル)
・がんCDK阻害剤の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Pfizer、Sanofi、Merck、Eli-Lilly、Bayer Pharmaceuticals、Syros Pharmaceuticals、Amgen、Cyclacel Pharmaceuticals)
・結論
【レポートの概要】

Market Analysis and Insights: Global Cancer CDK Inhibitors Market
The global Cancer CDK Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer CDK Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer CDK Inhibitors market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer CDK Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer CDK Inhibitors market.

Global Cancer CDK Inhibitors Scope and Market Size
Cancer CDK Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer CDK Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Preclinical
Phase-I
Phase-I/II
Phase-II
Phase-III

Segment by Application
Medical Institution
Scientific Research Center

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Sanofi
Merck
Eli-Lilly
Bayer Pharmaceuticals
Syros Pharmaceuticals
Amgen
Cyclacel Pharmaceuticals

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer CDK Inhibitors Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Preclinical
1.2.3 Phase-I
1.2.4 Phase-I/II
1.2.5 Phase-II
1.2.6 Phase-III
1.3 Market by Application
1.3.1 Global Cancer CDK Inhibitors Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Medical Institution
1.3.3 Scientific Research Center
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Cancer CDK Inhibitors Market Perspective (2016-2027)
2.2 Cancer CDK Inhibitors Growth Trends by Regions
2.2.1 Cancer CDK Inhibitors Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Cancer CDK Inhibitors Historic Market Share by Regions (2016-2021)
2.2.3 Cancer CDK Inhibitors Forecasted Market Size by Regions (2022-2027)
2.3 Cancer CDK Inhibitors Industry Dynamic
2.3.1 Cancer CDK Inhibitors Market Trends
2.3.2 Cancer CDK Inhibitors Market Drivers
2.3.3 Cancer CDK Inhibitors Market Challenges
2.3.4 Cancer CDK Inhibitors Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Cancer CDK Inhibitors Players by Revenue
3.1.1 Global Top Cancer CDK Inhibitors Players by Revenue (2016-2021)
3.1.2 Global Cancer CDK Inhibitors Revenue Market Share by Players (2016-2021)
3.2 Global Cancer CDK Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cancer CDK Inhibitors Revenue
3.4 Global Cancer CDK Inhibitors Market Concentration Ratio
3.4.1 Global Cancer CDK Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer CDK Inhibitors Revenue in 2020
3.5 Cancer CDK Inhibitors Key Players Head office and Area Served
3.6 Key Players Cancer CDK Inhibitors Product Solution and Service
3.7 Date of Enter into Cancer CDK Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Cancer CDK Inhibitors Breakdown Data by Type
4.1 Global Cancer CDK Inhibitors Historic Market Size by Type (2016-2021)
4.2 Global Cancer CDK Inhibitors Forecasted Market Size by Type (2022-2027)

5 Cancer CDK Inhibitors Breakdown Data by Application
5.1 Global Cancer CDK Inhibitors Historic Market Size by Application (2016-2021)
5.2 Global Cancer CDK Inhibitors Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Cancer CDK Inhibitors Market Size (2016-2027)
6.2 North America Cancer CDK Inhibitors Market Size by Type
6.2.1 North America Cancer CDK Inhibitors Market Size by Type (2016-2021)
6.2.2 North America Cancer CDK Inhibitors Market Size by Type (2022-2027)
6.2.3 North America Cancer CDK Inhibitors Market Size by Type (2016-2027)
6.3 North America Cancer CDK Inhibitors Market Size by Application
6.3.1 North America Cancer CDK Inhibitors Market Size by Application (2016-2021)
6.3.2 North America Cancer CDK Inhibitors Market Size by Application (2022-2027)
6.3.3 North America Cancer CDK Inhibitors Market Size by Application (2016-2027)
6.4 North America Cancer CDK Inhibitors Market Size by Country
6.4.1 North America Cancer CDK Inhibitors Market Size by Country (2016-2021)
6.4.2 North America Cancer CDK Inhibitors Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Cancer CDK Inhibitors Market Size (2016-2027)
7.2 Europe Cancer CDK Inhibitors Market Size by Type
7.2.1 Europe Cancer CDK Inhibitors Market Size by Type (2016-2021)
7.2.2 Europe Cancer CDK Inhibitors Market Size by Type (2022-2027)
7.2.3 Europe Cancer CDK Inhibitors Market Size by Type (2016-2027)
7.3 Europe Cancer CDK Inhibitors Market Size by Application
7.3.1 Europe Cancer CDK Inhibitors Market Size by Application (2016-2021)
7.3.2 Europe Cancer CDK Inhibitors Market Size by Application (2022-2027)
7.3.3 Europe Cancer CDK Inhibitors Market Size by Application (2016-2027)
7.4 Europe Cancer CDK Inhibitors Market Size by Country
7.4.1 Europe Cancer CDK Inhibitors Market Size by Country (2016-2021)
7.4.2 Europe Cancer CDK Inhibitors Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Cancer CDK Inhibitors Market Size (2016-2027)
8.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Type
8.2.1 Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2016-2027)
8.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Application
8.3.1 Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2016-2027)
8.4 Asia-Pacific Cancer CDK Inhibitors Market Size by Region
8.4.1 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Cancer CDK Inhibitors Market Size (2016-2027)
9.2 Latin America Cancer CDK Inhibitors Market Size by Type
9.2.1 Latin America Cancer CDK Inhibitors Market Size by Type (2016-2021)
9.2.2 Latin America Cancer CDK Inhibitors Market Size by Type (2022-2027)
9.2.3 Latin America Cancer CDK Inhibitors Market Size by Type (2016-2027)
9.3 Latin America Cancer CDK Inhibitors Market Size by Application
9.3.1 Latin America Cancer CDK Inhibitors Market Size by Application (2016-2021)
9.3.2 Latin America Cancer CDK Inhibitors Market Size by Application (2022-2027)
9.3.3 Latin America Cancer CDK Inhibitors Market Size by Application (2016-2027)
9.4 Latin America Cancer CDK Inhibitors Market Size by Country
9.4.1 Latin America Cancer CDK Inhibitors Market Size by Country (2016-2021)
9.4.2 Latin America Cancer CDK Inhibitors Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Cancer CDK Inhibitors Market Size (2016-2027)
10.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Type
10.2.1 Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2016-2027)
10.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Application
10.3.1 Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2016-2027)
10.4 Middle East & Africa Cancer CDK Inhibitors Market Size by Country
10.4.1 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Cancer CDK Inhibitors Introduction
11.1.4 Pfizer Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Cancer CDK Inhibitors Introduction
11.2.4 Sanofi Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Cancer CDK Inhibitors Introduction
11.3.4 Merck Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Eli-Lilly
11.4.1 Eli-Lilly Company Details
11.4.2 Eli-Lilly Business Overview
11.4.3 Eli-Lilly Cancer CDK Inhibitors Introduction
11.4.4 Eli-Lilly Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.4.5 Eli-Lilly Recent Development
11.5 Bayer Pharmaceuticals
11.5.1 Bayer Pharmaceuticals Company Details
11.5.2 Bayer Pharmaceuticals Business Overview
11.5.3 Bayer Pharmaceuticals Cancer CDK Inhibitors Introduction
11.5.4 Bayer Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.5.5 Bayer Pharmaceuticals Recent Development
11.6 Syros Pharmaceuticals
11.6.1 Syros Pharmaceuticals Company Details
11.6.2 Syros Pharmaceuticals Business Overview
11.6.3 Syros Pharmaceuticals Cancer CDK Inhibitors Introduction
11.6.4 Syros Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.6.5 Syros Pharmaceuticals Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Cancer CDK Inhibitors Introduction
11.7.4 Amgen Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.7.5 Amgen Recent Development
11.8 Cyclacel Pharmaceuticals
11.8.1 Cyclacel Pharmaceuticals Company Details
11.8.2 Cyclacel Pharmaceuticals Business Overview
11.8.3 Cyclacel Pharmaceuticals Cancer CDK Inhibitors Introduction
11.8.4 Cyclacel Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.8.5 Cyclacel Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ がんCDK阻害剤の世界市場規模・現状・予測2021年-2027年(Global Cancer CDK Inhibitors Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。